Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

MLA

Guarneri, V., et al. “Loss of HER2 Positivity and Prognosis after Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 24, no. 12, Dec. 2013, pp. 2990–94. EBSCOhost, https://doi.org/10.1093/annonc/mdt364.

APA

Guarneri, V., Dieci, M. V., Barbieri, E., Piacentini, F., Omarini, C., Ficarra, G., Bettelli, S., & Conte, P. F. (2013). Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 24(12), 2990–2994. https://doi.org/10.1093/annonc/mdt364

Chicago

Guarneri, V, M V Dieci, E Barbieri, F Piacentini, C Omarini, G Ficarra, S Bettelli, and P F Conte. 2013. “Loss of HER2 Positivity and Prognosis after Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 24 (12): 2990–94. doi:10.1093/annonc/mdt364.